Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Dana Pizzuti Sells 14,375 Shares

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNXGet Free Report) insider Dana Pizzuti sold 14,375 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $44.87, for a total value of $645,006.25. Following the sale, the insider now owns 28,507 shares of the company’s stock, valued at $1,279,109.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Dana Pizzuti also recently made the following trade(s):

  • On Monday, June 24th, Dana Pizzuti sold 9,500 shares of Crinetics Pharmaceuticals stock. The shares were sold at an average price of $45.73, for a total value of $434,435.00.
  • On Monday, April 15th, Dana Pizzuti sold 14,375 shares of Crinetics Pharmaceuticals stock. The shares were sold at an average price of $44.47, for a total value of $639,256.25.

Crinetics Pharmaceuticals Stock Down 0.8 %

NASDAQ:CRNX opened at $43.83 on Friday. The business’s 50 day moving average is $46.52 and its two-hundred day moving average is $42.30. Crinetics Pharmaceuticals, Inc. has a 52 week low of $15.76 and a 52 week high of $53.70.

Crinetics Pharmaceuticals (NASDAQ:CRNXGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.09). The company had revenue of $0.64 million during the quarter, compared to analyst estimates of $0.20 million. The company’s revenue was down 76.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.85) earnings per share. As a group, equities analysts expect that Crinetics Pharmaceuticals, Inc. will post -3.53 EPS for the current year.

Institutional Trading of Crinetics Pharmaceuticals

Several hedge funds have recently made changes to their positions in CRNX. Natixis Advisors L.P. lifted its holdings in shares of Crinetics Pharmaceuticals by 25.7% in the 3rd quarter. Natixis Advisors L.P. now owns 25,630 shares of the company’s stock worth $762,000 after purchasing an additional 5,243 shares during the last quarter. Glenmede Trust Co. NA acquired a new stake in Crinetics Pharmaceuticals in the 3rd quarter valued at approximately $224,000. Alps Advisors Inc. increased its position in Crinetics Pharmaceuticals by 1.6% in the 3rd quarter. Alps Advisors Inc. now owns 40,328 shares of the company’s stock valued at $1,199,000 after acquiring an additional 618 shares during the period. Wellington Management Group LLP increased its position in Crinetics Pharmaceuticals by 1.1% in the 3rd quarter. Wellington Management Group LLP now owns 3,640,235 shares of the company’s stock valued at $108,261,000 after acquiring an additional 38,523 shares during the period. Finally, Hudson Bay Capital Management LP acquired a new stake in Crinetics Pharmaceuticals in the 3rd quarter valued at approximately $223,000. Institutional investors own 98.51% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Jonestrading increased their target price on Crinetics Pharmaceuticals from $52.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday, March 20th. Morgan Stanley increased their target price on Crinetics Pharmaceuticals from $50.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, May 23rd. Piper Sandler reissued an “overweight” rating and issued a $97.00 price target on shares of Crinetics Pharmaceuticals in a report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Crinetics Pharmaceuticals in a report on Friday, June 28th. Finally, JMP Securities reissued a “market outperform” rating and issued a $80.00 price target on shares of Crinetics Pharmaceuticals in a report on Tuesday, June 4th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $62.50.

Get Our Latest Analysis on Crinetics Pharmaceuticals

Crinetics Pharmaceuticals Company Profile

(Get Free Report)

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.

Featured Articles

Insider Buying and Selling by Quarter for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.